Know Cancer

or
forgot password

A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-small Cell Lung Cancer

Thank you

Trial Information

A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer


Inclusion Criteria:



- Advanced or metastatic pretreated NSCLC

- Measurable disease

- Adequate hematologic, hepatic and renal functions

- ECOG Performance Status of 0-2

Exclusion Criteria:

- Inability to swallow capsules

- Recent significant cardiovascular disease

- Woman who are pregnant or breastfeeding

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

CA165-020

NCT ID:

NCT00099879

Start Date:

Completion Date:

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location

Local InstitutionChicago, Illinois  
Local InstitutionCorona, California  
Local InstitutionHamden, Connecticut  
Local InstitutionDuncansville, Pennsylvania  
Local InstitutionRome, Georgia  
Local InstitutionChattanooga, Tennessee  
Local InstitutionDetroit, Michigan